Progesterone Receptor Negative Active Not Recruiting Phase 2 Trials for Capecitabine (DB01101)

IndicationStatusPhase
DBCOND0038639 (Progesterone Receptor Negative)Active Not Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03044730Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by SurgeryTreatment